Search

Your search keyword '"Green, Damian"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Green, Damian" Remove constraint Author: "Green, Damian" Publisher elsevier Remove constraint Publisher: elsevier
18 results on '"Green, Damian"'

Search Results

1. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

2. Single-cell analysis of the multiple myeloma microenvironment after gamma-secretase inhibition and CAR T-cell therapy.

3. Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients.

4. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.

5. Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy.

6. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.

7. KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation.

8. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

9. The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.

10. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

11. Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

12. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

13. Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

14. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

15. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

16. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.

17. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.

18. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.

Catalog

Books, media, physical & digital resources